Novartis on the Biosimilar Attack

Novartis (NYSE: NVS  ) received final marketing approval today for only the second biosimilar product ever to gain a regulatory OK in the European Union.

Unlike small molecule compounds, biologics (sometimes known as biopharmaceuticals) are more complex molecules and often much harder to make generic copies of (if at all). Due to this molecular complexity, regulators in the United States and European Union have struggled in the past to develop guidelines for a way for biogeneric (biosimilar) compounds to gain marketing approval.

With this extra regulatory difficulty there has been only one biosimilar compound approved in the U.S., and until today only one in the European Union as well.

Novartis' biosimilar that received the go-ahead is a compound that mimics the effects of epoetin alfa, sold by Johnson and Johnson (NYSE: JNJ  ) as Eprex in the European Union and by Amgen (Nasdaq: AMGN  ) and JNJ as Epogen in the United States. The drug is used to help with anemia related to kidney disease or chemotherapy. 

Novartis' epo compound was given the preliminary go-ahead by European regulators back in June, but because of a quirk of the European regulatory system, drugmakers have to wait an additional three months for final marketing approval -- which is always granted if the preliminary decision is positive.

The multibillion-dollar market for epo products in the EU has gotten much more crowded with Shire (Nasdaq: SHPGY  ) receiving approval for Dynepo and Roche getting a positive opinion on Micera this year. Approval of Novartis' biosimilar makes it a triple whammy.

Looking for more Foolish drug stock coverage?  Check out the Fool's market-beatingRule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. Johnson and Johnson is an activeIncome Investor pick. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 07, 2010, at 4:32 AM, infoalcpl wrote:

    My colleagues and I have authored what we believe is India’s first ever complete mapping of the Biosimilars opportunity in India. The report is nowbeing made available to the general public.

    Various issues have been dealt with, such as:

    - Patent expirations

    - Regulatory frameworks

    - Infrastructure Requirements

    - Etc.

    If anyone is interested in this report, please contact me at (infoalcpl AT gmail DOT com), and I would send you the brochure and other details.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 536035, ~/Articles/ArticleHandler.aspx, 9/19/2014 10:09:46 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement